Literature DB >> 6138726

Nicotine cue in rats analysed with drugs acting on cholinergic and 5-hydroxytryptamine mechanisms.

I P Stolerman, J A Pratt, H S Garcha, V Giardini, R Kumar.   

Abstract

The nicotine discriminative stimulus (cue) has been used to characterize further the underlying receptor mechanisms. Rats were trained to discriminate the effects of nicotine in a standard, two-bar operant conditioning procedure with food reinforcement. Mecamylamine blocked both the discriminative effect of nicotine and the reducing effect on the response-rate. The block of the discriminative effect could not be overcome by increasing the dose of nicotine, whereas the block of the reducing effect on the response-rate could be reversed. Mecamylamine was effective when administered by either the subcutaneous or the intraventricular route, but hexamethonium was inactive by both routes. Mecamylamine, but not hexamethonium, blocked the discriminative effect of the nicotinic cholinergic agonist, cytisine. Methergoline did not block the discriminative effects of nicotine, even in doses considerably larger than those which blocked the discriminative effects of the 5-HT agonist, quipazine. Mecamylamine did not block the effects of quipazine. The results are consistent with the view that the nicotinic cue is mediated primarily through cholinergic receptors, and that 5-HT mechanisms are not involved. The block of the quipazine cue supports the view that the discriminative effects of this drug are mediated through 5-HT receptors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6138726     DOI: 10.1016/0028-3908(83)90021-7

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  24 in total

1.  Enhanced attenuation of nicotine discrimination in rats by combining nicotine-specific antibodies with a nicotinic receptor antagonist.

Authors:  Mark G LeSage; David Shelley; Marco Pravetoni; Paul R Pentel
Journal:  Pharmacol Biochem Behav       Date:  2012-04-04       Impact factor: 3.533

Review 2.  Neuropharmacology of the interoceptive stimulus properties of nicotine.

Authors:  Thomas E Wooters; Rick A Bevins; Michael T Bardo
Journal:  Curr Drug Abuse Rev       Date:  2009-09

Review 3.  Health consequences of using smokeless tobacco: summary of the Advisory Committee's report to the Surgeon General.

Authors:  J W Cullen; W Blot; J Henningfield; G Boyd; R Mecklenburg; M M Massey
Journal:  Public Health Rep       Date:  1986 Jul-Aug       Impact factor: 2.792

4.  Reversal of overshadowing in a drug mixture discrimination in rats.

Authors:  J A White; I P Stolerman
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

5.  Discriminative stimulus effects of mecamylamine and nicotine in rhesus monkeys: Central and peripheral mechanisms.

Authors:  Colin S Cunningham; Megan J Moerke; Lance R McMahon
Journal:  Pharmacol Biochem Behav       Date:  2019-02-06       Impact factor: 3.533

Review 6.  Trends in drug discrimination research analysed with a cross-indexed bibliography, 1982-1983.

Authors:  I P Stolerman; P J Shine
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

7.  Chronic central nicotinic blockade after a single administration of the bisquaternary ganglion-blocking drug chlorisondamine.

Authors:  P B Clarke
Journal:  Br J Pharmacol       Date:  1984-10       Impact factor: 8.739

8.  Patterns of nicotinic receptor antagonism II: cardiovascular effects in rats.

Authors:  Emily M Jutkiewicz; Kenner C Rice; F Ivy Carroll; James H Woods
Journal:  Drug Alcohol Depend       Date:  2013-01-18       Impact factor: 4.492

Review 9.  Potential therapeutic uses of mecamylamine and its stereoisomers.

Authors:  Justin R Nickell; Vladimir P Grinevich; Kiran B Siripurapu; Andrew M Smith; Linda P Dwoskin
Journal:  Pharmacol Biochem Behav       Date:  2013-04-18       Impact factor: 3.533

10.  Nicotine cue in rats: effects of central administration of ganglion-blocking drugs.

Authors:  R Kumar; C Reavill; I P Stolerman
Journal:  Br J Pharmacol       Date:  1987-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.